Bristol-Myers Squibb Co banner

Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 60.13 USD -0.82% Market Closed
Market Cap: $122.4B

Relative Value

The Relative Value of one BMY stock under the Base Case scenario is hidden USD. Compared to the current market price of 60.13 USD, Bristol-Myers Squibb Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BMY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

BMY Competitors Multiples
Bristol-Myers Squibb Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Bristol-Myers Squibb Co
NYSE:BMY
121B USD 2.5 17.2 7.2 8.9
US
Eli Lilly and Co
NYSE:LLY
946.1B USD 14.5 45.8 30.9 33
US
Johnson & Johnson
NYSE:JNJ
586.8B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
267.4B CHF 4.3 20.8 12.2 13.8
UK
AstraZeneca PLC
LSE:AZN
226.4B GBP 5.2 29.7 16.4 23.2
CH
Novartis AG
SIX:NOVN
234.9B CHF 5.4 21.6 13.4 17.2
US
Merck & Co Inc
NYSE:MRK
289.8B USD 4.5 15.9 9.9 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.3
US
Pfizer Inc
NYSE:PFE
154.4B USD 2.5 19.9 7.7 10.2
UK
GlaxoSmithKline PLC
LSE:GSK
83.7B GBP 2.6 14.6 7.5 10.6
P/E Multiple
Earnings Growth PEG
US
Bristol-Myers Squibb Co
NYSE:BMY
Average P/E: 21.8
17.2
16%
1.1
US
Eli Lilly and Co
NYSE:LLY
45.8
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
20.8
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.7
26%
1.1
CH
Novartis AG
SIX:NOVN
21.6
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
US
Pfizer Inc
NYSE:PFE
19.9
22%
0.9
UK
GlaxoSmithKline PLC
LSE:GSK
14.6
14%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Bristol-Myers Squibb Co
NYSE:BMY
Average EV/EBITDA: 43
7.2
-10%
N/A
US
Eli Lilly and Co
NYSE:LLY
30.9
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
12.2
6%
2
UK
AstraZeneca PLC
LSE:AZN
16.4
13%
1.3
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Bristol-Myers Squibb Co
NYSE:BMY
Average EV/EBIT: 92.9
8.9
-7%
N/A
US
Eli Lilly and Co
NYSE:LLY
33
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.7
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.8
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
23.2
21%
1.1
CH
Novartis AG
SIX:NOVN
17.2
9%
1.9
US
Merck & Co Inc
NYSE:MRK
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
3%
3.1
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
10.6
7%
1.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett